Last reviewed · How we verify
LIPO-102
LIPO-102 is a Small molecule drug developed by Neothetics, Inc. It is currently in Phase 2 development.
LIPO-102 is a small molecule used in clinical trials for various conditions, including Thyroid-Related Eye Disease, Subcutaneous Adipose Tissue Reduction, Abdominal Contour Defects, and Subcutaneous Abdominal Adiposity. It has been studied in pilot trials, including a single-masked, placebo-controlled study for patients with symptomatic exophthalmos associated with Thyroid-related Eye Disease.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LIPO-102 |
|---|---|
| Sponsor | Neothetics, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity (PHASE2)
- An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity (PHASE2)
- Dose-ranging Study (PHASE2)
- Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED) (PHASE2)
- An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers (PHASE1)
- Dose Ranging and Dose Frequency of LIPO-102 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIPO-102 CI brief — competitive landscape report
- LIPO-102 updates RSS · CI watch RSS
- Neothetics, Inc portfolio CI
Frequently asked questions about LIPO-102
What is LIPO-102?
Who makes LIPO-102?
What development phase is LIPO-102 in?
Related
- Manufacturer: Neothetics, Inc — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing